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Lack of common TCRA and TCRB clonotypes in CD8þ /
TCRabþ T-cell large granular lymphocyte leukemia: a review
on the role of antigenic selection in the immunopathogenesis
of CD8þ T-LGL
Y Sandberg1, MJ Kallemeijn1, WA Dik1, D Tielemans1, ILM Wolvers-Tettero1, EJ van Gastel-Mol1, T Szczepanski1,2, Y Pol1, N Darzentas3,
JJM van Dongen1 and AW Langerak1
Clonal CD8þ /T-cell receptor (TCR)abþ T-cell large granular lymphocyte (T-LGL) proliferations constitute the most common subtype
of T-LGL leukemia. Although the etiology of T-LGL leukemia is largely unknown, it has been hypothesized that chronic antigenic
stimulation contributes to the pathogenesis of this disorder. In the present study, we explored the association between expanded
TCR-Vb and TCR-Va clonotypes in a cohort of 26 CD8þ /TCRabþ T-LGL leukemia patients, in conjunction with the HLA-ABC
genotype, to find indications for common antigenic stimuli. In addition, we applied purpose-built sophisticated computational tools
for an in-depth evaluation of clustering of TCRb (TCRB) complementarity determining region 3 (CDR3) amino-acid LGL clonotypes.
We observed a lack of clear TCRA and TCRB CDR3 homology in CD8þ /TCRabþ T-LGL, with only low level similarity between small
numbers of cases. This is in strong contrast to the homology that is seen in CD4þ /TCRabþ T-LGL and TCRgdþ T-LGL and thus
underlines the idea that the LGL types have different etiopathogenesis. The heterogeneity of clonal CD8þ /TCRabþ T-LGL
proliferations might in fact suggest that multiple pathogens or autoantigens are involved.
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INTRODUCTION
Large granular lymphocyte (LGL) proliferations are derived
from normal cytotoxic LGL cells, which comprise 10–15% of
peripheral blood (PB) mononuclear cells (MNCs).1–3 The majority
of the normal LGL cells (85%) are of NK-cell origin, and a
minority is derived from mature (post-thymic) T lymphocytes.
Lymphoproliferations of LGLs range from activated polyclonal
expansions to clinically overt leukemias. T-cell LGL (T-LGL)
leukemia is the most common subtype, representing B85% of
all LGL leukemia cases diagnosed in western countries.
T-LGL leukemia is a rare and heterogeneous disorder and about
one-third of patients is asymptomatic at diagnosis. The main
clinical manifestations are related to chronic neutropenia and/or
anemia. 3–7 There is a frequent association with a wide variety of
autoimmune diseases (33%) and other malignancies (13%).8
Its diagnosis is based on a persistent (46 months) morphologically
and/or immunophenotypically increased clonal CD3þ /CD57þ LGL
population in PB, usually 42 109/l, though a lower count (range
0.4–2 109/l) may also be compatible with a diagnosis of T-LGL
leukemia.9,10 T-LGL leukemias can be divided into three groups
on the basis of their immunophenotypical and molecular
characteristics: CD8þ , CD4þ and T-cell receptor (TCR)gdþ T-LGL.
Monoclonal CD8þ /TCRabþ T-LGL leukemia forms the largest
subgroup (80–90%) of monoclonal T-LGL lymphoproliferative
disorders.11 It presents in elderly individuals (mean age 60 years)
and generally has an indolent clinical course.3,12 However, cases
with a more aggressive clinical course that are associated with a
CD3þ /CD8þ /CD56þ /CD57 phenotype have been reported as
well.13,14 CD3þ /CD4þ /TCRabþ T-LGL leukemia and CD3þ /
TCRgdþ T-LGL leukemia are far less common (o5 and 5–10%,
respectively), but a considerable number of cases from both
disease entities have recently been described in detail.15,16
Clonality assessment via PCR-based studies of TCR genes is
essential to discriminate true T-LGL leukemia from other reactive
proliferations. It should be stressed that the finding of clonality
does not necessarily imply malignancy in this disease, since most
cases are indolent and do not require therapy. Therefore, patients
are often diagnosed as having T-cell clonopathy of undetermined
significance.1,4,17
Although the etiology of T-LGL leukemia is still largely
unknown, it has been hypothesized that chronic antigenic
stimulation contributes to the pathogenesis of this disorder. This
is in line with the activation-associated effector phenotype and
the skewed TCR expression pattern found in T-LGL leukemia.
An exaggerated response to immunodominant autoantigens
or viral/bacterial antigens might be the initial step in the
development of this disorder.18–21 Recently, the T-cell repertoire
has been demonstrated to be dynamic in a large proportion (37%)
of T-LGL leukemia patients, a phenomenon referred to as ‘clonal
drift’.22 This supports the hypothesis that extreme clonal evolution
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is the result of a polarized reactive process. On top of that,
secondary molecular events are assumed to be required to
establish the full leukemic phenotype of the chronically antigen-
stimulated T-LGL population. Those events especially lead to
dysregulated apoptosis and constitutively activation of multiple
cell survival pathways. 11,12,23–26
To further substantiate the potential involvement of a common
antigen in driving development of clonal T-LGL proliferations, the
complementarity determining region 3 (CDR3) sequences of
the rearranged TCR genes are being analyzed. The CDR3 region of
the TCR molecule has the highest antigenic specificity and directly
binds to the antigenic peptide presented in the context of HLA.27
Garrido et al.28 demonstrated strikingly similar motifs in CDR3
TCR-Vb13 sequences in 42% of CD4þ /TCRabþ T-LGL leukemia
cases and a clear association with the HLA-DR*0701 genotype.
Interestingly, highly similar CDR3 sequences could also be
detected in TCRg (TCRG) and TCRd (TCRD) genes in nearly half
of patients diagnosed with TCRgdþ T-LGL leukemia, supporting a
common antigen-driven origin of this disorder.16
In CD8þ /TCRabþ T-LGL leukemia non-random clonal selection
has been suggested,18,29 even though no consistent single
structural homologous motif could be detected in CDR3
sequences of TCRb (TCRB) genes, The seeming lack of such
identical TCR specificities could however also be explained by the
diverse HLA background of these patients. Furthermore, the TCRa
chain might have an important role next to the TCRb chain,
especially in the initial phase of high-affinity clonal TCR
selection.30 However, the CDR3 regions of the TCRa (TCRA)
genes have not been extensively studied in CD8þ /TCRabþ T-LGL
leukemia.
In the present study, we therefore explored the existence of a
potential association between CDR3 sequences of both the TCRA
and TCRB clonotypes in a cohort of 26 patients diagnosed with
CD8þ /TCRabþ T-LGL leukemia in conjunction with the HLA
genotype. In addition, we applied purpose-built sophisticated
computational tools, specifically developed for sequence pattern
discovery in CDR3 amino-acid sequences to evaluate clustering of
a large number of TCRB CDR3 amino-acid clonotypes of CD8þ /
TCRabþ T-LGL leukemia patients.
MATERIALS AND METHODS
Patients and cell samples
PB and/or bone marrow (BM) samples from 26 patients with CD8þ /
TCRabþ T-LGL leukemia were obtained. The diagnosis of T-LGL leukemia
was established by clinical and laboratory parameters as defined
previously.7,9,31 Patients with a persistent (46 months) and increased
(41 109/l) monoclonal CD3þ /CD8þ /TCRabþ T-LGL proliferation in PB
were included. All patient samples were obtained according to the Helsinki
declaration following guidelines of the Medical Ethics Committee of
Erasmus MC, University Medical Center (Rotterdam, The Netherlands).
PB/BM MNCs were isolated by Ficoll-Paque (density: 1.077 g/ml; Pharmacia,
Uppsala, Sweden) centrifugation and were used for DNA isolation and RNA
isolation. Immunophenotyping was performed on whole PB or BM samples
and occasionally on MNC fractions. Cytomorphological May-Gru¨nwald-
Giemsa staining of PB smears was used for morphological evaluation of
LGLs. HLA genotyping for HLA-ABC was performed by Luminex-based
SSOP-PCR techniques (One Lambda Inc., Canoga Park, CA, USA).
Immunophenotypical analysis
Cells were analyzed for membrane expression using a routine panel of
monoclonal antibodies, including CD2, CD3, CD4, CD5, CD7, CD8, CD16,
CD56, CD57, anti-TCRab (BMA031 and WT31), anti-TCRgd (11F2) and anti-
HLA-DR. Immunofluorescence stainings were performed as described32
and evaluated on a FACSCalibur or FACSCanto II (BD Biosciences, San Jose,
CA, USA) flow cytometer. Data analysis was performed using CellQuest and
Paint-A-Gate Pro software (BD Biosciences).
The PB and/or BM samples were studied in more detail for Vb domain
expression to quantify the contribution of each Vb family to the CD8þ
lymphocyte population. To this end, flow-cytometric analysis was
performed using the IO Test Beta Mark kit (Beckman Coulter, Brea, CA,
USA) as described.32 Samples in which the Vb restriction of the expansion
could not be identified by flow cytometry were analyzed by TCRB RT–PCR
as described.33
DNA and RNA isolation and cDNA synthesis
High-molecular weight DNA from fresh or frozen PB MNCs was extracted
using a phenol-chloroform extraction-based protocol, followed by ethanol
precipitation and resolution in Tris-EDTA buffer.34 In a subset of cases, DNA
was isolated using the GenElute Mammalian Genomic DNA miniprep kit
(Sigma-Aldrich, St Louis, MO, USA) according to the manufacturer’s
protocol. Total RNA was extracted from fresh or frozen PB and/or BM
MNCs from patients and reverse transcribed into cDNA as previously
described.35 cDNA quality was checked using ABL as a control gene.
TCRA and TCRB gene rearrangement analysis
For TCRA gene rearrangement analysis, cDNA was amplified using newly
developed TCRA primers: one constant region reverse primer (Ca) and 54
different Va family-specific forward primers distributed over 5 different
multiplex tubes; each of these multiplex contained 10 (TCRA tube B) or 11
(TCRA tubes A, C, D and E) Va primers in combination with the Ca primer
(Supplementary Table 1). In each 50ml PCR, 2 ml of cDNA, 10 pmol of 50 and
30 oligonucleotide primers, 3mmol/l MgCl2, 0.2mmol/l dNTP, 5 ml 10
buffer II, and 1–2U AmpliTaq Gold polymerase (Applied Biosystems, Foster
City, CA, USA) were used.
TCRB gene rearrangement analysis was performed according to the
BIOMED-2 multiplex PCR protocol.36 BIOMED-2 multiplex PCR kits were
obtained from InVivoScribe Technologies (San Diego, CA, USA; http://
www.invivoscribe.com). Amplification reactions were performed in an
automated thermocycler (model ABI 2700; Applied Biosystems).
Sequence analysis
After PCR amplification of TCRA and TCRB gene rearrangements, products
were subjected to heteroduplex analysis.37 Products found to be
monoclonal in heteroduplex analysis were directly sequenced except for
cases with more than one clonal product. In such cases, homoduplexes
were excised from the polyacrylamide gel and DNA was eluted before
sequencing. Sequencing was performed on the ABI 3100 or 3130xl Genetic
Analyzers (Applied Biosystems), using the dye terminator cycle sequencing
kit and AmpliTaqFS DNA polymerase (Applied Biosystems). Assignment of
Vb, Db, Jb, Va and Ja genes and reading frames of the involved TCRB and
TCRA gene rearrangements was done using the IMGT database (http://
www.imgt.org).38
In silico analysis and data visualization
V-J combinatorial diversity was visualized using Circoletto, an online
visualization tool based on Circos (http://bat.ina.certh.gr/tools/circoletto/).39
The collected TCRB CDR3 amino-acid diversity was further analyzed
using the TEIRESIAS algorithm, a computational tool developed by the
Bioinformatics and Pattern Discovery group at the IBM Computational
Biology Center, as described previously.40 This algorithm uses a motif-
based clustering approach with predefined thresholds for amino-acid
identity and similarity, CDR3 length differences and offsets for sequence
motifs within CDR3 sequences.
TCRB CDR3 amino-acid patterns of different subsets were visualized
using Weblogo (http://weblogo.berkeley.edu/). Each logo consists of
multiple stacks of symbols, one stack for each position of the sequence.
CDR3 is shown based on IMGT position definitions.
RESULTS
Clinical and hematological features are heterogeneous in
CD8þ /TCRabþ T-LGL leukemia
The most relevant clinical and hematological findings at diagnosis
of the 26 CD8þ /TCRabþ T-LGL leukemia patients enrolled in this
study are summarized in Table 1. The median age was 58 years
(range 31–86 years) and there was no male or female
predominance. Out of the 26 patients, 21 (81%) were symptomatic
at presentation. Nine of the twenty-six patients (35%) had an
episode of bacterial infection or B symptoms (fever, night sweats
and weight loss). Most frequent presentations concerned
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neutropenia and/or anemia (62%), whereas some T-LGL leukemias
presented with neutropenia plus thrombocytopenia (12%).
Thrombocytopenia with coexistent anemia was found in just
one case (4%), splenomegaly in two (8%) and lymphadenopathy
also in only one (4%). Examination of PB smears showed an
increased number of LGLs with abundant cytoplasm containing
azurophilic granules in virtually all analyzed cases.
An associated disease was found in 11 cases (42%) (Table 1).
In our cohort, seven patients (27%) had a co-existent autoimmune
disorder. The most common autoimmune manifestation was
rheumatoid arthritis, which was diagnosed in three patients (12%).
Co-existence of a malignancy was found in five cases (18%), three
of which showed a second hematological malignancy (12%).
To compare the relative frequencies of associated cytopenias,
autoimmune disorders and malignancies in all three types of
T-LGL leukemia, we analyzed the clinical data of our CD8þ T-LGL
cohort (n¼ 26) and the data of 56 CD8þ T-LGL leukemia patients
described by Wlodarski et al.29 and compared those with the
clinical features of 36 patients with CD4þ T-LGL leukemia28 and
our cohort of 44 published16 and 19 novel TCRgdþ T-LGL
leukemia patients. On average, similar clinical features were
observed between CD8þ /TCRabþ T-LGL leukemia and TCRgdþ
T-LGL leukemia. Notably, the frequency of cytopenias and
autoimmune disorders appeared to be much lower in CD4þ /
TCRabþ T-LGL leukemia as compared with other types (Figure 1).
At closing of the study, the median follow-up of the patients
was 34 months (range 6–122 months). Two-thirds of patients
required therapy with one or more agents (Table 1).
The therapeutic strategy was largely aimed at improving
cytopenias and included erythrocyte transfusions and various
immunosuppressive drugs. We observed one disease-related
death in these 26 patients (case 86-041) which is in line with
the generally indolent clinical course of this disease.
Typical LGL immunophenotype is seen in all CD8þ /TCRabþ T-LGL
T-LGL cells of all 26 cases showed membrane co-expression of
CD3, CD8 and TCRab molecules. The majority of leukemic LGLs
expressed CD2 (100%), CD5 (77%) and CD7 (81%). Furthermore,
the T-LGL cells of all cases showed expression of one or more
markers like CD16, CD56 or CD57 that have typically been
associated with LGL and that reflect the antigen-experienced
nature of the cells (Table 1). Out of 22 cases 11 were CD16 positive
(50%), whereas CD56 expression was seen in 7 out of 20 cases
analyzed (35%). Heterogeneous expression of CD57 could
be demonstrated in 23 out of 24 evaluable cases (96%). Thus, these
CD8þ /TCRabþ T-LGLs show the typical effector T-cell phenotype.
TCRA and TCRB combinatorial diversity greatly differs between
CD8þ /TCRabþ T-LGL and CD4þ /TCRabþ T-LGL
To evaluate whether CD8þ /TCRabþ T-LGL shows signs of antigen
stimulation in their antigen receptors, we aimed for a compre-
hensive analysis of both the TCRa and the TCRb chain in parallel to
the HLA genotype.
First, we studied the clonotypic TCRB repertoire using specific
anti-TCR Vb domain MoAbs. Dominant TCR-Vb reactivity was
observed in 22 out of 26 cases (Table 2). All cases, including the
four cases without detectable TCR Vb expression, demonstrated
clonal in-frame TCRB gene rearrangements in multiplex PCR and/
or RT–PCR analysis (Table 3). Results of sequence analysis of Vb-Jb
Table 1. Characteristics, clinical presentation and immunophenotype of 26 patients diagnosed with CD8þ /TCRabþ T-LGL leukemia
Case
no.
Sample Age,
sex
Immunophenotype Main clinical presentationsa Associated disease LGL clone size
( 109/l)
Therapy
1 86-041 58, F CD2/3/8/5/7 Anemia PRCA 21.6 RBC transfusion,
chlorambucil
2 96-013 58, F CD2/3/8/16/56/57 Anemia/neutropenia — 13.0 Unknown
3 96-043 73, F CD2/3/8/5/7/16/56/57 Neutropenia/thrombocytopenia Oligo arthritis 9.9 MTX
4 92-050 50, M CD2/3/8/5/7/16neg/56neg/57/HLA DR Neutropenia RA (RFþ ), DLBCL 1.9 None
5 98-126 73, M CD2/3/8/5/7/16/56/57/HLA DR Anemia/thrombocytopenia HCC 1.0 Chlorambucil
6 92-024 55, F CD2/3/8/2/5/7/16/56neg/57/HLA DR Neutropenia/anemia AIHA, ITP, bronchus carcinoma 7.4 CSA
7 93-027 53, M CD2/3/8/5/7/16neg/56neg/57/HLA DR Anemia AIHA 2.0 Unknown
8 96-067 39, F CD2/3/8/5/16/57 Neutropenia — 5.9 None
9 97-064 71, M CD2/3/8/16neg/56neg/57/HLA DR neg Neutropenia — 1.2 Unknown
10 99-100 49, M CD2/3/8/5/7/16/56neg/57/HLA DR neg Anemia — 5.5 Unknown
11 98-194 38, F CD2/3/8/5/7/16/56/57neg/HLA DR Neutropenia — 6.6 None
12 05-060 70, M CD2/3/8/5/7/16neg/56neg/57/HLA DR Neutropenia/thrombocytopenia — 3.1 Unknown
13 05-100 31, F CD2/3/8/5/7/57 Neutropenia/anemia — 2.0 Corticosteroids,
CSA
14 05-191 73, M CD2/3/8/5/7/16neg/56neg/57/HLA DR Neutropenia/recurrent infections Chronic NK-LGL leukemia 4.4 MTX
15 03-030 41, F CD2/3/8/5/7neg/57/HLA DR Anemia/B symptoms PRCA 2.5 CSA
16 03-086 39, F CD2/3/8/5/7/16/56neg/57 Fatigue M. Hodgkin 2.0 None
17 00-113 72, M CD2/3/8/5neg/7/16neg/56neg/57/HLA
DRneg
Neutropenia/ B symptoms — 3.5 None
18 93-054 62, M CD2/3/8/7/16neg/57 Anemia/splenomegaly/B symptoms Chronic osteomyelitis,
melanoma
4.4 Chlorambucil,
RBC transfusion
19 02-047 76, F CD2/3/8/5/7/57/HLA DR B symptoms — 12.0 None
20 91-004 86, F CD2/3/8/7/16neg/56neg Neutropenia/anemia/ lymphadenopathy — 3.8 None
21 05-281 59, M CD2/3/8/5/7neg/16neg/56/57/HLA DRneg B symptoms — 2.7 None
22 06-026 67, M CD2neg/3/8/5/7/16/56neg/57/HLA DRneg Neutropenia/B symptoms/
thrombocytopenia
(Oligo) RA 2.0 HCQ
23 06-038 69, M CD2/3/8/5neg/7/16neg/56neg/57/HLA DR Neutropenia RA 3.2 MTX
24 06-127 35, F CD2/3/8/5/7/16/56neg/57/HLA DR Neutropenia — 3.7 None
25 06-131 61, F CD2/3/8/5/7/16neg/56/57/HLA DR Recurrent infections — 1.2 None
26 06-246 47, F CD2/3/8/5/7/16/56/57/HLA DR Neutropenia/splenomegaly — 10.2 CSA
Abbreviations: AIHA, autoimmune hemolytic anemia; CSA, cyclosporin A; DLBCL, diffuse large B-cell lymphoma; HCC, hepatocellular carcinoma; HCQ,
hydroxychloroquine; ITP, idiopathic thrombocytopenic purpura; MTX, methotrexate; PRCA, pure red cell aplasia; RA, rheumatoid arthritis; RBC, red blood cell;
RF, rheumatoid factor; TCR, T-cell receptor; T-LGL, T-cell large granular lymphocyte. aNeutropenia was defined as absolute neutrophil count (ANC)o1.5 109
neutrophils/l; anemia was defined as hemoglobin level o10 g/dl; thrombocytopenia was defined as platelet count o150 109/l.
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gene rearrangements and Vb protein/mRNA expression were
concordant in all cases. On the basis of these results, a slight
predominance of Vb2, Vb5 and Vb12 was noted. Jb2 genes were
used more frequently than Jb1 genes (62 vs 38%), with the Jb2.1
proportion being highest (15%). This Jb2 predominance is in line
with the non-random Jb gene distribution as it is known from
mature polyclonal PB TCRabþ T cells of healthy individuals.41
To study the clonotypic TCRA repertoire, we developed a novel
multiplex RT-PCR assay. Using this assay, clonal TCRA gene
rearrangements could be demonstrated in all 22 cases that were
analyzed (Table 2). In the remaining four cases no RNA could
be isolated due to lack of material. Similar to Vb usage, there was
also no common Va gene usage among the 22 patients studied.
Genes from the Va19, Va8 and Va12 families were used most
frequently, being expressed in three cases each. Ja gene usage
was also highly diverse (Table 4).
When visualizing the TCRA and TCRB combinatorial diversity
using the Circoletto tool, both the Va-Ja and Vb-Jb diversities were
indeed largely random in CD8þ /TCRabþ T-LGL (Figures 2a and b).
This is in strong contrast to the non-random distribution of Vb-Jb
combinations as seen in monoclonal CD4þ /TCRabþ T-LGL
lymphocytosis patients.28 (Figure 2c); unfortunately, from these
CD4þ /TCRabþ T-LGLs no Va-Ja combinatorial data are available
for a direct comparison of the TCRA combinatorial diversity. For a
complete picture on the combinatorial diversity of all three T-LGL
subtypes, we also analyzed the Vg-Jg and Vd-Jd combinations in
our cohort of 63 TCRgdþ LGL patients using Circoletto. Similar to
the diversity in CD4þ /TCRabþT-LGL, but unlike CD8þ /TCRabþ
T-LGL, the combinatorial diversity in TCRG and TCRD appeared to
be non-random as well (Figures 2d and e). It should be noted that
the lower number of V genes might already impact on the more
limited combinatorial diversity of these two loci.
Finally, we evaluated the HLA-ABC genotype of the CD8þ /
TCRabþ T-LGL patients. No clear predominance of HLA-A, -B or -C
alleles or combinations thereof was observed (Table 2). When
evaluating the expanded Vb and Va families in conjunction with
the HLA-ABC alleles, also no clear association was observed
between a particular TCR-Va/Vb specificity and the involved HLA
genotype.
Collectively, these data show a clear heterogeneity in the
combinatorial diversity of the TCR clonotypes in CD8þ /TCRabþ
T-LGL, which does not seem to be directly linked to the HLA
genotype. This heterogeneity clearly differs from the more
homogeneous patterns seen in TCRgdþ T-LGL and especially
CD4þ /TCRabþ T-LGL.
Lack of common TCRA and TCRB CDR3 motifs in CD8þ /TCRabþ
T-LGL
Given the lack of skewing of TCRA and TCRB combinatorial
diversity, we then explored the possibility of a more subtle TCR
homology in CD8þ /TCRabþ T-LGL leukemia patients. To this end,
we analyzed TCRA and TCRB junctional diversity by studying CDR3
sequences in more detail. A total of 24 T-LGL TCRA CDR3
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Figure 1. Relative frequency (%) of associated cytopenias, auto-
immune diseases and malignancies in CD8þ /TCRabþ , CD4þ /
TCRabþ and TCRgdþ T-LGL leukemia.
Table 2. HLA genotype and Va/Vb usage in CD8þ /TCRabþ T-LGL leukemia patients
Case no. Sample no. LGL expansion Expanded TCR Vb familya Expanded TCR Va familyb HLA-A HLA-B HLA-C
1 86-041 Oligoclonal Vb1 Va19 02, 11 35, 50 04, 06
2 96-013 Oligoclonal Vb12 Va19 02, 68 40, 44 03, 07
3 96-043 Monoclonal Vb22 Va29 01, 25 07, 08 03, 07
4 92-050 Oligoclonal Vb23 Va17 02, 02 13, 15 03, 12
5 98-126 Oligoclonal Vb2 Va19 ND ND ND
6 92-024 Monoclonal Vb7.2 Va12.2 01, 24 08, 40 03, 07
7 93-027 Oligoclonal Vb8.1/8.2 Va6 02, 02 40, 40 03, 03
8 96-067 Oligoclonal No reactivity (Vb6 in PCR) Va26 02, 31 27, 58 02, 07
9 97-064 Oligoclonal Vb13 Va35 24, 29 45, 49 06, 07
10 99-100 Monoclonal Vb17 Va23 01, 02 08, 41 07, 17
11 98-194 Biclonal No reactivity (Vb6/Vb12 in PCR) Va6/Va21 02, 03 07, 27 01, 07
12 05-060 Monoclonal Vb17 Va30/Va26 03, 32 41, 55 03, 17
13 05-100 Monoclonal Vb16 Va12.2 02, 03 18, 51 05, 14
14 05-191 Monoclonal Vb5 Va1 02, 02 15, 35 03, 04
15 03-030 Biclonal No reactivity (Vb6/Vb16 in PCR) ND 02, 02 08, 08 07, 07
16 03-086 Monoclonal Vb14 Va3 02, 03 08, 35 04, 07
17 00-113 Monoclonal Vb8.2 Va8 01, 26 38, 44 05, 12
18 93-054 Oligoclonal Vb12/Vb15 Va12.3 01, 02 15, 57 03, 06
19 02-047 Monoclonal Vb7.2 Va8 ND ND ND
20 91-004 Biclonal Vb5/Vb6 Va41 ND ND ND
21 05-281 Monoclonal Vb2 Va1.2 ND ND ND
22 06-026 Monoclonal No reactivity (Vb24 in PCR) Va29 ND ND ND
23 06-038 Monoclonal Vb2 Va12.1 01, 24 08, 18 05, 07
24 06-127 Monoclonal Vb13 ND 01, 11 27, 35 02, 04
25 06-131 Monoclonal Vb12 ND ND ND ND
26 06-246 Monoclonal Vb5.1 ND ND ND ND
Abbreviations: ND, not done; TCR, T-cell receptor; T-LGL, T-cell large granular lymphocyte. aDominant TCR Vb family usage defined by immunophenotyping
and molecular analysis. bDominant TCR Va family usage defined by molecular analysis.
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Table 3. Amino-acid sequences of CDR3 motifs of in-frame TCRB rearranged alleles in patients with CD8þ /TCRabþ T-LGL leukemia
Case no. Sample no. Rearrangement V N-(D)-N J
1 86-041 Vb1-Jb2.1 C A S S L S G R A L N E Q F F
2 96-013 Vb12.1-Jb2.2 C A I S E G S G P G E L F F
3 96-043 Vb22-Jb2.6 C A S G G D R G T G A N V L T F
4 92-050 Vb23-Jb1.5 C A S S L G G R Y S N Q P Q H F
5 98-126 Vb2-Jb1.3 C S A S L G G R P T I A G N T I Y F
6 92-024 Vb7.2-Jb1.5 C A S S Q D V R P P P E D R P Y S N Q P Q H F
7 93-027 Vb8.2-Jb2.5 C A S S L G T G G M E T Q Y F
8 96-067 Vb6.2-Jb2.1 C A S S L A H S Y N E Q F F
9 97-064 Vb13.3-Jb2.7 C G S L G Q G A W Y E Q Y F
10 99-100 Vb17-Jb2.7 C A S S P E S L F S Y E Q Y F
11 98-194 Vb6.4-Jb1.1 C A R S F S P S L D T S S L F V E A F F
Vb12.3-Jb2.3 C A S S C Y Q P G L D L P R A D T Q Y F
12 05-060 Vb17-Jb2.7 C A S S I F R G N E Q Y F
13 05-100 Vb16-Jb2.5 C A S S P V G A Y P K E T Q Y F
14 05-191 Vb5.1-Jb1.4 C A S S L A K G K G A T N E K L F F
15 03-030 ND
16 03-086 Vb14-Jb2.1 C A S N N R G S Y N E Q F F
17 00-113 Vb8.2-Jb1.5 C A S S W G G N Q P Q H F
18 93-054 Vb12.1-Jb2.3 C A I S G R L A G G R T S T D T Q Y F
19 02-047 Vb7.2-Jb2.2 C A S G G V G G G E L F F
20 91-004 Vb5.6-Jb2.1 C A S S L D N Y N E Q F F
Vb6.5-Jb1.1 C A S S F S P Y T R P E A F F
21 05-281 Vb2-Jb1.4 C A V P T G R N E K L F F
22 06-026 Vb24-Jb2.7 C A T S R D L L T Y E Q Y F
23 06-038 Vb2-Jb2.5 C S A R N G P N Y Q E T Q Y F
24 06-127 Vb13.6-Jb1.5 C A S S Y G S P L D I D S A I S P Q H F
25 06-131 Vb12.2-Jb1.2 C A S S P K G Y G Y T F
26 06-246 Vb5.1-Jb1.2 C A S S L G S G Y G Y T F
Abbreviations: CDR3, complementarity determining region 3; ND, not done; TCRB, T-cell receptor b; T-LGL, T-cell large granular lymphocyte.
A L I V G(P): neutral side chain; D E: acidic side chain; S T: aliphatic side chain; N Q: amide side chain; K R H: basic side chain; M: sulfur-containing side chain;
F Y W: cyclic side chain.
Table 4. Amino-acid sequences of CDR3 motifs of in-frame TCRA rearranged alleles in patients with CD8þ /TCRabþ T-LGL leukaemia
Case no. Sample no. Rearrangement V N-(D)-N J
1 86-041 Va19-Ja49 C A L S E S G G N Q F Y F
2 96-013 Va19-Ja26 C A L S E G S R F Y G Q N F V F
3 96-043 Va29-Ja52 C G R V A G G T S F
4 92-050 Va17-Ja20 C A T L S S N D Y K L S F
5 98-126 Va19-Ja37 C A L S E A E G S S N T G K L I F
6 92-024 Va12.2-Ja53 C A V T G G S N Y K L T F
7 93-027 Va6-Ja21 C V G F N K F Y F
8 96-067 Va26.2-Ja20 C I P S P S N D Y K L S F
9 97-064 Va35-Ja49 C A G F T G N Q F Y F
10 99-100 Va23-Ja52 C A A P V G G T S Y G K L T F
11 98-194 Va8.6-Ja56 C A V S L T G A N S K L T F
Va21-Ja57 C A V K G G S E K L V F
12 05-060 Va26.2-Ja24 C I L R D V E S W G K F Q F
Va30-Ja44 C G T P G N G T A S K L T F
13 05-100 Va12.2-Ja23 C A V Q G G K L I F
14 05-191 Va1.1-Ja10 C A V D P G L A A G G N K L T F
15 03-030 ND
16 03-086 Va3-Ja36 C A S D Q T G A N N L F F
17 00-113 Va8.1-Ja28 C A V M Y S G A G S Y Q L T F
18 93-054 Va12.3-Ja9 C A M S A V M R G F K T I F
19 02-047 Va8.1-Ja39 C A V M S D A G N M L T F
20 91-004 Va41-Ja48 C A V N F
21 05-281 Va1-2-Ja33 C A T L D S N Y Q L I W
22 06-026 Va29-Ja45 C A A K G F G L T F
23 06-038 Va12.1-Ja34 C V V K S Y N T D K L I F
24 06-127 ND
25 06-131 ND
26 06-246 ND
Abbreviations: CDR3, complementarity determining region 3; ND, not done; TCRA, T-cell receptor a; T-LGL, T-cell large granular lymphocyte.
A L I V G (P): neutral side chain; D E: acidic side chain; S T: aliphatic side chain; N Q: amide side chain; K R H: basic side chain; C M: sulfur-containing side chain;
F Y W: cyclic side chain.
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clonotypes from 22 patients and 27 T-LGL TCRB CDR3 clonotypes
from 25 patients were evaluated, but the TCRA and TCRB CDR3
motifs of the immunodominant T-cell clones did not show clearly
identical sequences (Tables 3 and 4).
To exclude the possibility that the number of evaluable TCRB
CDR3 sequences was limiting the possibility to find clear
similarities, additional CDR3 sequences that had been published
in the literature were included for further analysis. In this way,
81 additional TCRB CDR3 motifs of a large series of 56 CD8þ /
TCRabþ T-LGL leukemia patients29 could be evaluated. Similar to
our cohort, in a proportion of patients more than one
immunodominant clone was found, suggesting that some T-LGL
proliferations are biclonal. In this extended data set, the Vb-Jb
combinatorial diversity appeared to be equally heterogeneous
(Supplementary Figure 1) as in our own cohort.
For a more comprehensive evaluation of CDR3 motifs,
detailed in silico analysis was performed on the 108 combined
TCRB CDR3 sequences in parallel to 14 TCRB CDR3 sequences of
earlier described CD4þ T-LGL.28 By applying a recently described
sequence motif-based clustering methodology40 using thresholds
of 50% amino-acid identity and 70% similarity between any two
CDR3 sequences, 13 out of 14 CD4þ T-LGL displayed a highly
homogeneous and similar TCR with clear similarities in length and
amino-acid positions in the CDR3 sequence logo (Figure 3a). The
similarity of the CDR3 sequence logo was even more impressive
when concentrating on a higher level cluster of 11 CD4þ T-LGL
cases that are all characterized by TCRVb13.1-Jb1.1 rearrange-
ments (Figure 3b). This is in line with the proposed CMV antigen-
driven selection in the pathogenesis of this type of T-LGL.
Interestingly, the two CD4þ T-LGL that were slightly different from
the other 11 CD4þ T-LGLs based on Jb1.5 usage did show low
level clustering with two CD8þ T-LGLs,
as evidenced from the common Jb1.5 and Vb8/Vb13 gene usage,
and the CDR3 sequence logo (Figure 3c). Finally, some clustering
was seen between four other CD8þ T-LGL cases that were
characterized by Jb2.3/2.7 usage and a CDR3 length of 12
(Figure 3d). Unfortunately not enough TCRA sequences were
available for a meaningful in silico TCRA CDR3 analysis.
Collectively the in silico analyses illustrate that, in strong
contrast to CD4þ T-LGL, CD8þ T-LGL do not show clear and
consistent signs of TCR homology that would reflect involvement
of a common antigen.
DISCUSSION
Molecular analysis of the TCR repertoire can be a powerful tool in
the study of T-cell responses to pathogens and in autoimmune
diseases. Thus, analysis of the TCR expression pattern in patients
with T-LGL leukemia might provide insight into the pathogenesis
of this disorder. Similar TCR clonotypes between T-LGL clones of
different patients would in that respect be suggestive of a
common antigenic stimulus underlying the pathogenesis of this
disorder. Furthermore, it has been suggested that the cytopenias
associated with T-LGL leukemia would be the result of highly
specific recognition and killing of individual hematopoietic cell
lineages by T-LGL clones.
In the present study, we identified and characterized TCR
clonotypes in a group of CD8þ /TCRabþ T-LGL leukemia patients.
We could not detect specific predominant Vb family usage in our
CD8þ /TCRabþ T-LGL cohort. Immunophenotypical analysis of
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Figure 2. Frequencies of V-J pairing in TCRabþ T-LGL and TCRgdþ T-LGL leukemia. Highly diverse Va-Ja (a) and Vb-Jb (b) combinations are
seen in our cohort of 26 patients with CD8þ T-LGL leukemia, while the Vb-Jb pairing is clearly non-random in monoclonal CD4þ T-LGL
proliferations (c). Also in TCRgdþ T-LGL leukemia limited combinatorial diversity of TCRG and TCR genes (d and e, respectively) is seen. (Blue to
purple rectangular bands) J genes and (red to cyan rectangular bands) V genes. The width of the bands is proportional to the number of times
the V and J genes are connected. This figure was generated using the Circos software package.47
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TCR Va expression has so far only been explored in a minority of
TCRabþ T-LGL leukemia cases. Likewise, complete sequencing of
TCRA gene rearrangements has only been performed in few
(n¼ 5) T-LGL leukemia patients, thus far not showing any signs of
common Va or Ja gene usage.42 In our cohort of 22 patients, we
could not detect preferential Va or Ja gene usage; moreover, TCRA
CDR3 sequence analysis did not show a common amino-acid
motif between the various patients, which is thus in line with the
TCRB results.
In silico analysis using a recent purpose-built bioinformatics
method did not identify common TCRB CDR3 amino-acid
sequences in a large cohort of CD8þ T-LGL leukemia patients.
This is in strong contrast to monoclonal CD4þ /Vb13.1þ T-LGL
proliferations, in which virtually all published TCRB CDR3
sequences can be assigned to one cluster with unique character-
istics. Our current results therefore underline the distinct
pathogenesis between the CD4þ and CD8þ T-LGL disease
entities.
On the basis of our findings, we did not find straightforward
evidence for common (super)antigen involvement in the patho-
genesis of CD8þ /TCRabþ T-LGL leukemia, since no immunodo-
minant clones with identical or highly similar TCRA and TCRB
CDR3 amino-acid sequences could be identified in a majority of
patients. In the study of Wlodarski et al.29 identical expanded
clonotypes were found in only 2 out of 56 patients. However,
clonotypes specific for malignant clones were not encountered to
a great extent in 172 clones from healthy individuals. We did not
encounter the 108 clonotypes of the 82 evaluated leukemic LGL
cases in CD8þ T cells of healthy individuals (data not shown),
although high-throughput analysis of the TCRB repertoire of
CD8þ T cells would be needed to draw firm conclusions. Recently,
deep sequencing of the T-cell repertoire in healthy controls and
CD8þ T-LGL leukemia has been performed and confirms that
T-LGL clonotypes are not present in the general public and are
therefore private to the disease.43
The heterogeneity of TCR clonotypes in clonal CD8þ /TCRabþ
T-LGL proliferations is partially explained by the presence of
biclonal LGL proliferations and clonal switching. Both have been
described in T-LGL leukemia and are suggestive of pervasive
antigenic drive.22 In addition, Clemente et al.43 recently
demonstrated that individual T-LGL clones were present at basal
levels in almost all other T-LGL leukemia cases. This suggests the
presence of an as yet undefined mechanism whereby certain
clonotypes may predispose an individual toward the extreme
monoclonal expansions commonly found in T-LGL leukemia.43
Another explanation for the seemingly low level of similarity
between the dominant clonotypes in our study might be the large
variability in HLA genotype in our patient series. Peptide binding is
affected through the physical amino-acid properties and the
tertiary CDR3 structure. Therefore, the linear amino-acid homology
comparisons might not be the most appropriate method to
identify common motifs in TCR molecules.
Altogether this may suggest that CD8þ /TCRabþ T-LGL clones
could have evolved in a stepwise manner from an initial
polyclonal/oligoclonal immune response directed against multiple
(auto)antigenic targets. Following an exaggerated immune
response, secondary molecular events would then lead to global
deregulation of cell proliferation and survival of one or a few
clonotypes. Among the survival signalling pathways, the Janus
kinase/signal transducer and activator of transcription (JAK/STAT)
pathway has been associated with LGL transformation.26 Most
recently, the role of STAT family genes (STAT3 and STAT5b) in the
pathogenesis of T-LGL leukemia has been emphasized.44
Activating somatic mutations in STAT3 were found in up to 40%
of T-LGL leukemia patients and it has been suggested that
mutational analysis of STAT3 might distinguish true T-LGL
leukemia cases from clonally skewed reactive processes.11,45,46
In summary, no clear indications for common TCRA or TCRB
CDR3 motifs were found in our CD8þ /TCRabþ T-LGL cohort.
When clonotypes of our 26 patients were cross-referenced against
the previously reported clonotypic database of 56 T-LGL leukemia
patients, we could only identify homologous clonotypes between
a limited number of patients. This is in contrast to the shared
clonotypes as seen in CD4þ /TCRabþ and TCRgdþ T-LGL leukemia
and might point to a more random clonal selection in TCRabþ
T-LGL leukemia. The heterogeneity of clonal CD8þ /TCRabþ T-LGL
proliferations might in fact suggest that multiple pathogens or
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Figure 3. Sequence logos of selected subsets in T-LGL leukemia.
(a) Subset 1 comprises 13 Vb13.1-Jb1.1/ Jb1.5 gene rearrangements
in CD4þ T-LGL leukemia cases, characterized by pronounced overall
similarity. (b) The largest high-level subset in the present study is
present in subset 2, comprising clonally expanded CD4þ T-LGL
showing Vb13.1-Jb1.1. (c) Low level clustering was seen in Vb8/
Vb13-Jb1.5 gene rearrangements in two CD4þ LGL and two CD8þ
LGL cases. (d) Some higher level clustering is present in Vbn.-Jb2.3/
2.7 gene rearrangements in four CD8þ T-LGL leukemia cases. The
height of symbols within the stack indicates the relative frequency
of each amino acid at that position. Amino-acid position is
according to the IMGT numbering for the V domain. This figure
was generated using WebLogo (http://weblogo.berkeley.edu/).
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autoantigens are involved. Additional studies taking into account
the triad of HLA genotype, peptide-groove binding and TCR
specificity are needed to precisely define the impact of (auto)-
antigen stimulation in the pathogenesis of CD8þ /TCRabþ T-LGL
leukemia.
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